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6/j.bThe clinical advantage of pharmacokinetic (PK)-directed–based dosing on intravenous (i.v.) versus oral
busulfan-related toxicity and survival remains unclear. We performed a retrospective cohort study of
sequential cohorts of patients comparing PK-directed oral and i.v. busulfan-based conditioning regimens in
lymphoma patients undergoing autologous hematopoietic cell transplantation (ASCT). Patients received
oral (n5 95), every 6 hours i.v. (IV16, n5 113), or once-daily i.v. (IV4, n5 86) busulfan, cyclophosphamide,
and etoposide. PK-directed dosing was performed to achieve a predefined target area under the curve
(AUC) of 20,000 mM-min (range: 18,400-21,600 mM-min). PK-directed dose adjustments markedly reduced
the number of patients in the oral group with total AUC higher than the targeted AUC range, and reduced
the variations of total AUC values in all patient groups. One hundred–day mortality was 2.1%, 3.6%, and 3.5%
for oral, IV16, and IV4 cohorts, respectively. Five-year overall survival (OS) was 57% (95% confidence interval
[CI] 45%-66%) and 64% (95% CI 53%-73%) for patients who received oral and i.v. busulfan, respectively. Both
multivariable and instrumental variable analyses indicated the route of delivery had no significant impact on
OS, whereas refractory disease and age $55 were significantly associated with poorer OS. In lymphoma
patients undergoing ASCT, PK-directed i.v. or oral busulfan-based conditioning regimens have comparable
toxicity and OS.
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To date, there are no prospective, randomized
clinical trials for determining the optimal conditioning
regimens for hematopoietic stem cell transplantation
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bmt.2012.02.006high-intensity conditioning regimens provide retro-
spective comparisons of the toxicity of oral versus in-
travenous (i.v.) busulfan administration, with limited
information regarding the efficiency of pharmacoki-
netic (PK)-directed busulfan dosing in the setting of
autologous HSCT. Comparisons of overall survival
(OS) between i.v. and oral busulfan have not been per-
formed when PK-directed dosing is applied in both
contexts [1]. In addition, daily i.v. administration of
busulfan via PK-directed dosing may offer conve-
nience over 4 times daily dosing with highly predict-
able pharmacokinetics [2]. However, the efficacy of
this regimen has not been well studied in comparison
to alternative busulfan dosing regimens.
In addition to the clinical considerations above,
HSCT remains a highly costly procedure [3], which
justifies the need for economic evaluation of factors
that impact HSCT. Multiple reports have highlighted
the importance of initial hospital stay in the total cost1287
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ration of neutropenia and shortening the length of
hospital stay [5] as strategies to reduce costs. With re-
spect to the conditioning regimen, the cost of i.v. bu-
sulfan constitutes a significant incremental expense
compared with oral delivery, which should be counter-
balanced by reduced toxicity and/or improved efficacy
[1]. We hypothesized that i.v. administration of busul-
fan with a targeted area under the curve (AUC) of
20,000 mM-min (range: 18,400-21,600 mM-min) may
provide improved efficiency in achieving the target
AUC level with safety and efficacy comparable to
oral busulfan, and designed a retrospective cohort
study to perform this comparison.MATERIALS AND METHODS
Design
This retrospective, observational cohort was con-
ducted with a preexisting database populated with
Hodgkin’s lymphoma (HL) and non-Hodgkin lym-
phoma (NHL) patients undergoing their first autolo-
gous stem cell transplantation (ASCT) at Emory
Hospital between July 20, 1999, and May 19, 2010
(n 5 294). In May 2004, our program changed the
standard of care from oral to i.v. busulfan. The Emory
institutional review board approved use of patient data
for this analysis. Patients received either oral (1 mg/kg
every 6 hours 4 days from day28 to day25, n5 95)
or IV16 (0.9 mg/kg every 6 hours for 16 doses from
day 28 to day 25, n 5 113), or IV4 (3.6 mg/kg daily
 4 from day 28 to day 25, n 5 86), followed by cy-
clophosphamide (Cy, 60 mg/kg every day  2 on days
23 and22) and, etoposide (E, 10 mg/kg every day 3
on day 24 to day 22). Busulfan was dosed using ideal
body weight if the ratio of total body weight to ideal
body weight ratio was #1.3; otherwise, busulfan was
dosed according to an adjusted body weight, calculated
as the ideal weight plus 25% of the difference of total
and ideal weights. For patients weighing less than ideal
body weight, busulfan was dosed on total body. E and
Cy were based upon an average of ideal and actual
body weight for patients whose weight exceeded their
ideal body weight by a factor of 1.3 or greater, and ac-
tual body weight for patients whose weight was\1.3
their ideal body weight. Following oral busulfan ad-
ministration, half or full doses were readministered if
vomiting occurred\ or .60 minutes following any
single dose, respectively. Following 1 day of no che-
motherapy (day 21), patients received infusion of
autologous bone marrow cells or granulocyte colony-
stimulating factor–mobilized peripheral blood stem
cells that had been previously collected, frozen,
and thawed immediately before infusion as
previously reported [6]. A minimum dose of 2  106
CD341 cells/kg was required for transplantation.Severe hepatic veno-occlusive disease (HVOD) was
diagnosed based on Baltimore criteria [7].
PK-Directed Dosing
In this study, following the initial i.v. or oral dose,
PK monitoring of busulfan plasma levels was accom-
plished using the high-performance liquid chroma-
tography method with mass spectrometry by
Department of Pathology and Laboratory Medicine
at Emory University School of Medicine and Emory
Healthcare Systems. The predicted total AUC was
calculated by extrapolating the AUC derived from
PK analysis of the first dose of busulfan. Before
2003, PK-directed dosing modifications were applied
only to patients with predicted total AUC .24,000
mM-min. Since 2003, all patient doses were adjusted
to deliver an average total AUC of 20,000 mM-min
(range: 18,400-21,600 mM-min). The busulfan AUC
and elimination half-life were calculated using a com-
bination of linear and logarithmic trapezoidal rules as
described by Grochow [8]. The AUC during infusion
was calculated using the linear rule, and the postinfu-
sion AUC was calculated using the logarithmic rule.
For first dose levels, the AUC from the last concen-
tration to infinity was calculated using the elimination
rate constant determined by regression of the log-
transformed levels of the elimination phase.
Statistical Methods
The median value of the continuous variables
was used as a cutoff point for exploratory analysis.
Categoric variables including sex, race, diagnosis,
and disease status at transplantation were compared
by regimens and route of administration using chi-
square tests. Disease status at transplantation was
classified into 4 categories based on treatment re-
sponse according to the definition by the American
Society for Bone Marrow Transplantation and Center
for International Blood and Marrow Transplant
Research. They are complete remission (CR)1 or
CRu1 (CR1 with the exception of persistent scan
abnormalities of unknown significance) as category I;
CR2 or CRu2 as category II; PR (partial remission)1,
PR2, or CR3 as category III; and refractory disease
as category IV. The 100-day transplant-related mor-
tality was defined as death within 100 days posttrans-
plantation without relapse or disease progression. OS
was defined as the time from transplantation to last
follow-up or death irrespective of the cause of
death. Probabilities of OS were calculated using the
Kaplan-Meier estimate; the log-rank test was used
for univariate comparisons. Association of patients’
characteristics with outcomes was evaluated with step-
wise Cox proportional hazards regression models.
Hazard ratios (HR) are presented with a 95% confi-
dence interval (CI). Factors associated with a P value
Table 1. Route of Busulfan Delivery by Year of Trans-
plantation (n 5 294)
1999-2001 2002-2004 2005-2006 2007-2008 2009-2010 Total
Oral 34 61 0 0 0 95
IV16 0 21 74 18 0 113
IV4 0 0 0 38 48 86
Biol Blood Marrow Transplant 18:1287-1294, 2012 1289Outcomes of PK-Directed High-Dose i.v. and Oral Busulfan\.10 by univariate analysis and factors with a priori
clinical relevance were included in the final model.
All tests were 2 sided, with a5 0.05 for determination
of statistical significance. Multiple comparison correc-
tions were conducted with the Bonferroni adjustment.
Statistical analyses were performed with SAS version
9.2 (SAS Institute, Cary, NC).
To reduce the bias in this retrospective study be-
cause of adoption of new supportive care and treat-
ment protocols, an instrumental variable analysis was
applied under the 2 key assumptions: the instrument
should have statistically significant impact on the route
of administration; and the instrument should not be
associated with overall survival [9-11]. The analysis
took a 2-stage estimation approach, that is, the first
stage predicts the instrument and other baseline
factors, and the second-stage estimates the effect of
the route on OS incorporating the ‘‘instrumental vari-
able’’ derived from the first-stage estimation using
a Cox regression model [12].RESULTS
Patient Characteristics
The route of busulfan administration differed by
year of transplantation, with each regimen occurring
in serial cohorts of patients (Table 1). The median
ages for patients receiving oral, IV16, and IV4 regi-
mens were 45, 47, and 47 years, respectively. Patients’
median age, race, lymphoma diagnosis, body surface
area, and CD341 cell count were comparable across
the regimens except that patients receiving IV16 bu-
sulfan dosing had a significantly higher body weight
index than the other 2 groups (Table 2). In addition,
the distribution of disease status at transplantation
was different across 3 regimens with a greater propor-
tion of patients with advanced disease status (category
III) receiving IV busulfan and with refractory disease
status (category IV) receiving oral busulfan, respec-
tively. The majority of patients received peripheral
blood stem cells. Because treatment strategies were
utilized in a serial fashion, patients treated with oral
busulfan had significantly longer follow-up than those
receiving IV16 and IV4 busulfan.
Toxicity
Among patients who had an elevatedmaximumbil-
irubin ($2mg)within the first 30 days posttransplanta-
tion (oral group: n5 13, 14%; IV group: n5 38, 19%),none developed severe HVOD by Baltimore criteria.
Grade 3-4 neurotoxicities were not observed in any pa-
tients. There was no difference in the length of hospital
stay among 3 regimens. However, average hospital stay
was significantly longer for female patients (23.86 4.3
days) thanmale patients (22.56 3.4,P5 .0159), and for
African-American (AA) patients (AA, 24.3 6 4.8) than
non-AA (22.7 6 3.5, P5 .0071).Outcomes
The frequency of early death, occurring within the
first 100 days posttransplantation was not different for
patients receiving oral busulfan (2 deaths, 2.1%), IV16
(4 deaths, 3.5%), or IV4 (3 deaths, 3.5%, P 5 .512).
One-year and 2-year OS were comparable regardless
of the route of busulfan delivery or dosing regimen.
One-year OS for oral busulfan was 88.3% (95% CI
79.9-93.3), for IV16 was 80.3% (95% CI 71.1-86.8),
and for IV4 was 80.1% (95% CI 67.7-88.1). Two-year
OS for oral busulfan was 72.7% (95% CI 62.3-80.6),
and was 71.2% for IV16 dosing (95% CI 60.9-79.2).
Estimated 5-year OS for patients receiving i.v. busulfan
(combining IV16 and IV4 cohorts) showed a trend to-
ward better OS among recipients of i.v. busulfan com-
pared with that for patients receiving oral busulfan
(63.9%, 95% CI 52.7-73.1 versus 56.5%, 95% CI
45.3-66.3, respectively, P5 .10).
As the group receiving once-daily busulfan (IV4)
had relatively short median follow-up, both univariate
and multivariate analysis were performed comparing
the 2 groups receiving oral versus i.v. busulfan (comb-
ing IV16 and IV4) groups. Univariate analysis revealed
(Table 3) that age $55 years (HR 5 1.64, 95% CI
1.09-2.49) and refractory disease at the time of relapse
(HR 5 1.65, 95% CI 1.04-2.61), but not the route of
busulfan administration, were significantly associated
withOS (Figure 1). In addition, patients with a diagno-
sis of HL or patients with Karnofsky performance sta-
tus (KPS) .80 tended to have better OS than patients
with a diagnosis of NHL (HR 5 0.69, 95% CI 0.45-
1.06) or patients with lower KPS (HR 5 0.67, 95%
CI 0.44-1.02), respectively. Importantly, the change
in practice of PK-directed dosing, that is, changing
doses for AUC of .24,000 mM-min (before 2003)
versus changing doses for AUC outside of the target
range of 18,400-21,600 mM-min (after 2003) did not
have an impact on OS as indicated by log-rank testing.
The number of CD341 cells transplanted (less or
greater than the median value 7  106/kg), sex, and
race also had no impact on OS.
Consistent with univariate analyses, amultivariable
Cox proportional hazards regression model (Table 3)
showed that route of busulfan administration had
no effect on the OS, whereas age $55 (HR 5 1.67,
95% CI 1.09-2.56) and refractory disease status at
transplantation (HR 5 1.84, 95% CI 1.15-2.93) were
Table 2. Characteristics of the Transplanted Patients and Main Clinical Findings (Average with Minimum and Maximum)
Oral (n 5 95) IV16 (n 5 113) IV4 (n 5 86) P value*
Median age (years) 45 (19-66) 47 (17-69) 47 (18-66) .4105
>55 25 (26%) 35 (31%) 28 (33%) .406
Male/female 64/31 73/40 50/36 .412
Race .064
White, n 5 215 73 87 55
African American (AA), n 5 56 18 21 17
Asian, Hispanic, other, n 5 17 3 4 10
BSA 1.96 (1.56-2.60) 2.03 (1.44-2.84) 2.00 (1.58-2.53) .1242
Body mass index (kg/m2) 27.50 (17.86-53.63) 30.23 (17.41-62.65) 28.51 (18.41-45.30) .01
Diagnosis .713
HL, n 5 122 43 44 35
NHL, n 5 172 52 69 51
Disease status at transplantation <.0001
I: CR1/CRU1, n 5 45 10 (11%) 17 (15%) 18 (21%)
II: CR2/CRU2, n 5 65 27 (28%) 25 (22%) 13 (15%)
III: PR1/PR2/CR3, n 5 127 29 (30%) 47 (41%) 51 (59%)
IV: Primary refractory, n 5 53 25 (26%) 24 (21%) 4 (5%)
Median CD34+ count (106/kg bodyweight), n 5 263 5.62 (1.66-95.94), n 5 80 6.95 (2.98-68.25), n 5 106 6.47 (2.21-135.35), n 5 77 .3035
Source: PBSC† 95 113 86
Median KPS, n 5 273 80 (70-100), n 5 76 80 (70-100), n 5 111 90 (60-100), n 5 86 .003
Median length of hospitalization (days) 22.0 (2-42), n 5 74 22.0 (9-48), n 5 99 22.0 (12-43), n 5 85 <.01
Median follow-up (days) 1565 (10-4184) 929 (12-3311) 311 (33-845) <.0001
Maximum bilirubin by day 30 1.58 (0.5-22.4) 1.62 (0.6-10.4) 2.06 (0.6-10.6) .2144
BSA indicates body surface area; PBSC, peripheral blood stem cell.
*P value denotes the effect of conditioning regimen.
†There were 5, 2, and 1 patients receiving PBSC plus CD34+ in the oral, IV1, and IV4 groups, correspondingly. There were 2 patients receiving PBSC plus
bone marrow and 1 patient receiving bone marrow only in the oral group.
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Multivariate analysis revealed moderate association of
KPS .80 with reduced risk of mortality (HR 5 0.68,
95% CI 0.45-1.05). There was no interaction between
the route of administration with either disease status or
diagnosis. Despite differences in KPS for patients in
the oral, IV16, and IV4 groups (eg, percentage with
KPS .80 was 35%, 48%, and 74%, respectively, P
\ .0001), there was no significant interaction between
KPS and route of busulfan administration in the re-
gression model. Because i.v. busulfan had gradually re-
placed oral busulfan among patients treated after 2002,
we examined whether the year of transplantation could
be an instrumental variable affecting the choice of
treatment. Transplantation year was significantly asso-
ciated with the administration route (R2 5 .637, P\
.0001) but not with other baseline factors, including
sex, body mass index, diagnosis, age, race, and disease
status at relapse, and had no impact on OS. A 2-stage
instrumental variable analysis confirmed the findings
by the multivariate analysis that age $55 (HR 5
1.87, 95% CI 1.13-3.08), refractory disease status at
transplantation (HR 5 1.75, 95% CI 1.02-2.99), and
KPS .80 (HR 5 0.48, 95% CI 0.26-0.88), but
not route of administration (HR 5 1.60, 95% CI
0.89-2.84), had significant effects on OS. Female
patients also had significantly worse OS than male
patients (HR 5 1.88, 95% CI 1.15-3.08).
Pharmacokinetics
At the initial dose, 5 patients in the oral group
missed PK assessment because of vomiting, whereasnone of the patients in the IV groupsmissed PK assess-
ments, and 4 patients in the oral group were switched
to the IV16, group because of inability to take oral bu-
sulfan. By design, IV4 dosing resulted in significantly
higher initial AUC than the other 2 groups (P \
.0001). The half-life of busulfan following oral admin-
istration was significantly longer than that after i.v.
administration (Table 4, P 5 .001). Oral administra-
tions resulted in a significantly wider range of total
AUC than both the IV4 and IV16 groups (P 5
.0003; Figure 2A). More than one-quarter of patients
receiving i.v. busulfan had an initial total predicted
AUC within the target range (IV16 29%, IV4 28%),
whereas only 18% of patients receiving oral busulfan
had an initial total predicted AUC within the target
range of 18,400-21,600 mMol-min. In addition, the
majority of patients receiving oral busulfan (60%)
had an initial total predicted AUC above the targeted
range, whereas this only occurred in 19% of the
IV16 group and in 30% of the IV4 group (Figure 2A).
Regardless of dosing regimens, the majority of
patients (72%) had dose adjustments, and 109 patients
had repeated PK sampling (52%). When repeated PK
assessment was performed, the total predicted AUC
(for all doses) was not different comparing among
the IV groups, but a wide range of variation remained
in the oral group despite a similar mean AUC value to
those in the IV groups. Themajority of patients receiv-
ing IV16 (81%) and IV4 (82%) busulfan had total pre-
dicted AUC values in the target range, while 43% of
patients who received oral busulfan had total predicted
AUC values in the target range (P\ .0001), and 39%
Table 3. Univariate and Multivariate Analysis of Prognostic Factors for Overall Survival
Variable*
Univariate Multivariate Instrumental Variable Analysis
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
BMT year: per 1-year increase 1.06 (0.98-1.14) .152 — — — —
After 2003 versus before 2003 1.10 (0.71-1. 76) .629
Route: i.v. versus oral 1.06 (0.69-1.62) .781 1.12 (0.73-1.71) 0.611 1.60 (0.89-2.84) .114
Age: $55 versus <55 1.64 (1.09-2.49) .019 1. 67 (1.09-2.56) 0.018 1.87 (1.13-3.08) .014
Per 10-year increase 1.22 (1.06-1.44) .005
Disease status at relapse: increase in per category 1.24 (1.01-1.56) .054
III+IV versus I+II 1.50 (0.97-2.30) .065
Refractory versus chemosensitive disease 1.65 (1.04-2.61) .032 1.84 (1.15-2.93) 0.010 1.75 (1.02-2.99) .041
KPS: >80 versus #80 0.67 (0.44-1.02) .065 0.68 (0.45-1.05) 0.084 0.48 (0.26-0.88) .018
Sex: female versus male 1.16 (0.77-1.77) .473 — — 1.88 (1.15-3.08) .012
Diagnosis: HL versus NHL 0.69 (0.45-1.06) .091 — — — —
Race: AA versus non-AA 1.48 (0.91-2.40) .118 — — — —
CD34+ 106/kg: $ median value 7 versus <7 0.81 (0.54-1.21) .305 — — — —
*Within each variable, the reference for the analysis: BMT year before 2003, route with oral, age <55, chemosensitive disease at transplantation,
KPS #80, male, NHL, non-AA, CD34+ 106/kg with median value <7.
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dicted AUC values greater than the target range
(Figure 2B, Table 4).
The initial total predicted AUC was not correlated
with race, age, sex, diagnosis, disease status, transplan-
tation year, and performance status, but was signifi-
cantly associated with the busulfan plasma half-life
T1/2 (r 5 .2774, P\ .05). The total predicted AUC
recalculated following the dose adjustment was not
affected by these baseline variables.DISCUSSION
The current study reveals that lymphoma patients
undergoing ASCT after conditioning with a PK-
redirected high-dose busulfan, cyclophosphamide,
and etoposide (BuCyE) regimen had equivalent OS ir-
respective of the route of busulfan administration, with
no significant differences seen in the incidence of se-
vere HVOD or 100-day mortality comparing oral ver-
sus intravenous administration. Our report is largely
comparable to previously reported series using other
similar busulfan-based regimens [13,14]. Consistent
with previous reports [15,16], oral administration of
busulfan resulted in a longer serum half-life and widerFigure 1. Univariate analysis of prognostic factors on overall survival. The K
receiving autotransplants for NHL or HL after conditioning with BuCyE. Patient
plantation (age$ 55 versus younger), and chemosensitivity at transplantation (
were derived from the log-rank test.variation in AUC, with 43% of patients receiving oral
busulfan having a total predicted AUC within the tar-
get range, whereas more than 82% of patients receiv-
ing i.v. busulfan had a calculated total predicted
AUC in the target range following PK-directed dose
adjustments. These differences between oral and i.v.
dosing cohorts are partly because of practice changes
in dose adjustments, because many patients with low
AUC values receiving oral busulfan did not have
dose adjustments (increases) in contrast to more re-
cently treated patients in the i.v. cohorts in which all
patients with total predicted AUC above or below
the target range had dose adjustments. However,
39% of the patients receiving oral busulfan continued
to have total predicted AUC greater than the target
range following initial dose adjustments, suggesting
that the i.v. route may produce some efficiency in
achieving the target AUC. Overall this series indicates
that careful monitoring of drug levels following both
oral and i.v. busulfan administration can avoid ex-
tremely high cumulative drug levels, decreasing the
fraction of all patients with total predicted AUC above
the target range from 35% (before dose adjustments)
to 19% (after PK-directed dose adjustments). Of
note, only 6% of the recipients of i.v. busulfan hadaplan-Meier method was used to estimate overall survival for patients
s were stratified by route of administration (i.v. versus oral), age at trans-
primary refractory versus chemosensitive disease in PR or CR). P values
Table 4. Pharmacokinetic Characteristics
Oral IV16 IV4
All patients n 5 95 n 5 113 n 5 86
Starting dose (mg; mean ± SD) 65.6 ± 6.4 63.3 ± 10.6* 254.3 ± 40.2†
T1/2 (minutes; mean ± SD) 222.6 ± 104.3 190.1 ± 58.4† 188.5 ± 26.2†
Initial total predicted AUC
(mM-min; mean ± SD)‡
22,379 ± 5288
(n 5 78)
18,607 ± 3499†
(n 5 103)
20,228 ± 4737†
(n 5 84)
% at targeted AUC 18% (n 5 14) 29% (n 5 30)† 28% (n 5 24)†
% above targeted AUC 60% (n 5 47) 19% (n 5 20)† 30% (n 5 25)†
% below targeted AUC 22% (n 5 17) 52% (n 5 53)† 42% (n 5 35)†
% patients with dose adjustments 80% (n 5 75) 66% (n 5 75) 71% (n 5 61)
Adjusted dose (mg; mean ± SD) 61.2 ± 15.6 67.7 ± 16.0 253.5 ± 91.0†
T1/2 (minutes; mean ± SD) 234.6 ± 73.7 198.4 ± 40.1† 194.1 ± 35.0†
Total predicted AUC after dose adjustment (mM-min; mean ± SD) 20,584 ± 3005 19,431 ± 1313† 20,201 ± 1557
% at targeted AUC§ 43% (n 5 32) 81% (n 5 61)† 82% (n 5 50)†
% above targeted AUC 39% (n 5 29) 4% (n 5 3)† 15% (n 5 9)†
% below targeted AUC 19% (n 5 14) 15% (n 5 11) 3% (n 5 2)†
*The first 16 patients treated with IV16 dosing received 0.8 mg/kg every 6 hours; the dose was increased to 0.9 mg/kg every 6 hours for the subsequent
97 patients, following an analysis that showed 65% of the AUC values were below and only 26% of the AUC values were within the target range.
†Comparison of either IV16 or IV4 with oral group with significance level P < .05.
‡The number of patients with initial total AUC (n 5 265) was used as the denominator for the percentage calculation. Patients who received multiple
dose adjustments were only counted once.
§Percentage was calculated with the patients receiving dose adjustments (total of 211) as the denominator for each group.
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utilizing PK-directed dose adjustments dramatically
reduced the range of variation in total predicted
AUC among all conditioning regimen groups com-
pared with those values in the initial total predicted
AUC (Table 4). The low fraction of patients with
high total predicted AUC may have contributed to
the low 100-day mortality and absence of severe
HVOD reported in this single institution experience.
A limitation of this study is that it is retrospective
and limited to transplant patients who were treated
at a single institution. Because the study spanned
a 11-year period, the data on the time of relapse was in-
complete, especially for patients who had returned to
the care of their initial oncologist. Because .80% of
deaths among transplant recipients were because of
disease progression, OS most appropriately represents
disease control in this series. Other limitations of this
study include the modest sample size and practice-
based protocols for PK-directed dosing. Additionally,
the lack of complete data on some of the important
prognostic factors, such as treatment history and co-
morbidity scores, and the key outcome measures,
such as response duration, limit the analysis of theFigure 2. Histograms of total predicted AUC based on dosing regimen. (A)
among patients treated with the IV16 (n 5 113), IV4 (n 5 86), and oral (
PK-directed dose adjustment among patients treated with the IV16 (n 5 75),comparative effectiveness of the BuCyE regimens
studied.
The 1-year and 5-year survival for the IV groups
(combining IV16 and IV4) in this series are remarkably
similar to what has been reported in previous studies
of busulfan-based [13,14,17] and nonbusulfan-based
conditioning regimens [18] for lymphoma patients un-
dergoing ASCT. The current study had sufficient pa-
tients in the once-daily dosing IV4 group (n 5 86) to
conclude that these patients have similar 100-day mor-
tality and 1-year OS to those receiving every 6-hour
i.v. dosing, similar to the conclusions of a randomized
study of PK-directed IV4 versus IV16 conditioning
regimens (n 5 30/group) [19]. Our reported 5-year
OS in the cohort of patients receiving oral busulfan
is consistent with a previous report in HL patients
with a median age of 33 [20], and is corroborated by
a recent study using the United States Surveillance,
Epidemiology, and End Results data for patients
with diffuse large B-cell lymphoma [21]. A phase II
clinical trial currently being pursued is assessing the
toxicity and efficacy of PK-directed once-daily i.v.
administration of busulfan in combination with cyclo-
phosphamide and etoposide compared with a matchedHistograms of total predicted busulfan AUC following the initial dose
n 5 95) regimens. (B) Histograms of total predicted AUC following
IV4 (n 5 61), and oral (n 5 75) regimens.
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with carmustine, etoposide, cytarabine, and melphalan
(BEAM) regimen. This prospective, multicenter study
will help determine if our single-institution results
from PK-directed dosing can be reproduced.
However, in contrast with previous reports, the
present study has shown comparable efficacy and tox-
icity between regimens utilizing oral and i.v. delivery
of busulfan. This could be because of several reasons:
(1) PK-directed dosing adjustment may overcome
the greater interpatient variation in busulfan AUC
seen in patients receiving an oral drug; (2) the use of
a conservative AUC target and narrow AUC target
range of 20,0006 1600 mMol-min; (3) a lower median
age of patients in the current series (47 years) com-
pared with the reported studies [13,14,17]. In
particular, other published series have utilized
a broader target AUC (16,000-24,000), with a lower
percentage of patients receiving PK-directed dose ad-
justment.
The effect of race and ethnicity on PK profiles
and efficacy has been largely understudied in cancer
drugs [22], and the limited numbers of minority pa-
tients undergoing HSCT [23] has made it difficult to
use ethnicity as a covariate in prognostic models.
The unusually high percentage of AA in this study
population (19%) reflects the high AA population in
the state of Georgia (31% of the population), which
is significantly greater than the national average
(12.6%) based on the 2010 U.S. Census Bureau report
(http://2010.census.gov/2010census/data/). The cur-
rent study found that AA patients and the female pa-
tient group had a longer hospitalization, but this
disparity was not reflected in differences in OS.
Nevertheless, our study indicates very similar clinical
outcomes and pharmacokinetics parameters for AA
lymphoma patients versus non-AA lymphoma patients
undergoing high-dose busulfan-based conditioning
and autologous HSCT.
Although the current study did not include a phar-
maco-economic analysis, the equivalent survival and
similar lengths of hospitalization comparing recipients
of oral and i.v. busulfan formulations make it unlikely
that a formal cost-effectiveness comparison would
favor i.v. busulfan. Although the overall cost of i.v. bu-
sulfan regimens can be reduced if PK-directed dose ad-
justments are eliminated, a substantial fraction of
patients receiving i.v. busulfan in this series (68%)
had dose-adjustments following PK measurements. It
is unknown if outcomes for patients receiving i.v. bu-
sulfan with total predicted AUC above or below the
target range (without PK-directed dose adjustments)
would be similar to the outcomes measurements re-
ported herein. Alternatively, once-daily i.v. delivery
of busulfan with PK monitoring could be potentially
cost-effective if fewer dose adjustments are required
compared with the administration of oral busulfan.In light of the higher cost of the i.v. formulation,
a larger, prospective study would be needed to deter-
mine if the reduced need for repeated PK monitoring
in the administration of i.v. busulfan and the slight
improvement in OS by i.v. over the oral busulfan-
based regimen we observed in the present study would
justify the added expense.
In conclusion, PK-directed i.v. and oral delivery
of busulfan resulted in total predicted AUC largely
within a well-defined targeted range for lymphoma
patients undergoing autologous ASCT. Because pa-
tients that received PK-directed i.v. and oral busulfan
had similar toxicity and OS, either route can be utilized
when PK-directed dose adjustments are being per-
formed to optimize busulfan dosing. Future studies are
needed to determine whether the improvement in OS
identified in this study for i.v. over oral PK-directed
busulfan-dosing is present in other settings.ACKNOWLEDGMENTS
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